. A Phase 2 Trial of the Efficacy and Safety of the Alpha7 Agonist Abt-126 as an Add-On Treatment in Mild-to-Moderate Alzheimer's Dementia. Alzheimers Dement. 2014 Jul;10(4 Suppl):P917-8.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Nelonicline